A randomized controlled protocol on the effect of moxibustion on the cardiac function and quality of life in patients with chronic heart failure

Jierong He, MB\textsuperscript{a}\textsuperscript{*}, Lihong Jiao, MB\textsuperscript{a}, Miao Xu, MM\textsuperscript{b}, Rui Gong, MB\textsuperscript{b}, Zhengyu Guo, MB\textsuperscript{c}\textsuperscript{*}

Abstract

Background: Chronic heart failure (CHF) is the final result of various cardiovascular diseases, with high morbidity and high mortality, which seriously threaten people’s health and quality of life. It has become a public health problem in the world. There is currently no specific treatment. Moxibustion, as a complementary and replacement therapy, has advantages in the treatment of chronic heart failure, but it lacks standard clinical studies to verify it. Therefore, the purpose of this randomized controlled trial is to evaluate the effect of moxibustion on the heart function and quality of life of patients with CHF.

Methods: This is a prospective randomized controlled trial to study the effect of moxibustion on the heart function and quality of life of patients with CHF. This is approved by the clinical research ethics committee of our hospital. Patients were randomly divided into observation group (moxibustion combined with Western medicine treatment group) or control group (conventional Western medicine treatment group). There is a follow-up for 3 months after 6 weeks of treatment. Observation indicators include total effective rate of cardiac function improvement, Minnesota Living with Heart Failure Questionnaire, left ventricular ejection fraction, N-terminal pro-brain natriuretic peptide, 6-minute walk test, adverse reactions, etc. Data were analyzed using the statistical software package SPSS version 18.0 (Chicago, IL).

Discussion: This study will evaluate the clinical efficacy of moxibustion in the treatment of CHF. The results of this study will provide a reliable reference for the clinical choice of moxibustion as an adjuvant treatment for chronic heart failure.

Trial registration: OSF Registration number: DOI 10.17605/OSF.IO/29XE7.

Abbreviations: 6MWTD = 6-minute walk test, CHF = chronic heart failure, CONSORT = Consolidated Standards of Reporting Trials, NYHA = New York Heart Association, RCT = randomized controlled trial.

Keywords: chronic heart failure, moxibustion, protocol, randomized controlled trial

1. Introduction

Chronic heart failure is the final result of various cardiovascular diseases. It has the characteristics of high morbidity, high mortality, and high rehospitalization rate. It affects at least 26 million people worldwide and seriously threatens the lives and health of patients. It has become a world public health problem.\textsuperscript{1,2} According to data from 2019, in the United States, an estimated 6.2 million adults suffer from chronic heart failure (CHF). Among adults 65 years of age and older, 21 out of 1000 elderly people are affected by heart failure.\textsuperscript{3} Although the current treatment strategy for CHF has made progress, there are a variety of treatment options, such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta blockers and aldosterone antagonists, coronary revascularization, implantable cardioverter-defibrillators, etc, but the results are not satisfactory.\textsuperscript{4}\textsuperscript{6,7} The latest data from an international prospective cohort study of congestive heart failure show that the total mortality rate of CHF within 1 year is still 16.5%,\textsuperscript{5} Therefore, it is still necessary to explore complementary and alternative therapies to optimize the treatment strategy of CHF.

Moxibustion is an external TCM treatment based on the meridian theory. It has been widely used in the treatment of various diseases including cardiovascular diseases and has shown good curative effects.\textsuperscript{6,8} The curative effect of moxibustion mainly comes from the thermal effect of moxa burning on acupuncture points on the body surface,\textsuperscript{8} and the chemical stimulation of the medicinal ingredients in the wormwood.\textsuperscript{9,10} Animal experiments have found that moxibustion plays a key role in myocardial protection by regulating neuroendocrine immune response, inhibiting excessive autophagy, and improving myocardial hypertrophy and cardiac function.\textsuperscript{11,12} The mechanism may be related to the upregulating of mTOR, inhibiting myocardial autophagy, and enhancing anti-inflammatory
responses. Previous systematic reviews have confirmed that moxibustion or acupuncture combined with conventional Western medicine is better than traditional treatment group, but due to factors such as limited research quality, small sample size, and short follow-up time, there is still no reliable clinical evidence to verify moxibustion as a complementary and alternative therapy on the heart function and quality of life of patients with chronic heart failure. Therefore, we plan to evaluate the effectiveness and safety of moxibustion on chronic heart failure through this randomized controlled trial.

2. Materials and methods

2.1. Study design

This is a prospective randomized controlled trial to study the clinical efficacy of moxibustion in the treatment of chronic heart failure. This study will follow the comprehensive trial reporting standards, and the flowchart is shown in Figure 1.

2.2. Ethics and registration

This research protocol complies with the Declaration of Helsinki and passed the review of the clinical research ethics committee of our hospital. This experiment has been registered in (registration number: DOI 10.17605/OSF.IO/29XE7). Before randomization, all patients were required to sign an informed consent form, and they can choose whether to continue the trial at any time.

2.3. Sample size

The calculation of sample size is based on the mean and standard deviation of Minnesota Living with Heart Failure Questionnaire score after the end of treatment. According to the results of the

---

Figure 1. Flow diagram.
failure,

Doppler ultrasound showed left ventricular ejection fraction <50%. The age ranged from 18 to 75 years old; New York Heart Association (NYHA) grades III to IV; Patients had strong compliance and signed an informed consent form.

Exclusion criteria: Patients with heart failure induced by other diseases such as congenital heart disease; Combined with other serious diseases such as malignant tumors, etc; Other heart diseases such as severe arrhythmia, etc; Combined with severe mental diseases; For this study, patients who are allergic to medication or have contraindications; Patients with skin ulceration at the moxibustion site.

2.5. Study design

Eligible participants were randomly assigned to the treatment group or the control group at a ratio of 1:1 using a random tool based on the central network. An independent statistician who was not involved in the implementation of the experiment or statistical analysis used SAS 9.3 software (SAS Institute, Cary, NC) to generate random sequences. The clinical research coordinator entered the participant’s information on the tablet and was given a random number. The research assistant gets the participant’s assignment from the computer. Throughout the research process, the research assistant is responsible for screening, recruiting participants, and assigning random numbers to the participants who have been included. Considering the operational nature of the intervention method, participants and operating physicians may be aware of random allocation. However, the evaluators of research results and the statisticians of data statistics and analysis have no knowledge of the distribution.

2.6. Intervention

2.6.1. Moxibustion treatment. The patient takes the supine position and fully exposes the acupoints. The acupoints of moxibustion are: Qihai, Guanyuan, Bilateral Zusanli, Bilateral Bloodhai. Cut the moxa stick (1.8 × 20 cm, Nanyang Hanyi Moxa Co Ltd, Nanyang, China) into 5 cm pieces, put it in a moxibustion box (23 × 16 × 9.2 cm, Nanyang Hanyi Moxa Co) after lighting, and then the moxibustion box is placed on the selected acupuncture point. The moxa was ignited on the iron gauze, which is in the lower part of the box. And the lid is replaced. If the patient reported a sensation of burning, the moxibustion box was opened or the box briefly lifted just above the skin, then put back in place. Remove the moxibustion box after 30 minutes. The whole procedure was performed in accordance with the State Standard of the People’s Republic of China Manipulation of Acupuncture and Moxibustion: Part 1 Moxibustion (GB/T 21709.1-2008). The treatment time was 30 minutes every other day.

2.6.2. Conventional Western medicine treatment. Oral spironolactone tablets (Zhongxin Pharmaceutical, Guoyao Zhunzi H10910011, Beijing, China), 20 mg each time, once a day; oral benazepril hydrochloride tablets (Novartis Pharmaceutical, Guoyao Zhunzi H20000292, Beijing, China), 20 mg each time, once a day; oral bisoprolol fumarate tablets (Yuandong Pharmaceutical, Guoyao Zhunzi H20083008, Chengdu, China), 10 mg each time, once a day; Digoxin tablets (Hangzhou Minsheng Pharmaceutical, Guoyao Zhunzi H133021657, Hangzhou, China), 0.5 mg each time, once a day.

The observation group was treated with moxibustion combined with Western medicine; the control group was treated with Western medicine alone. Both groups of patients completed 6 weeks of standard treatment.

2.7. Evaluation criteria and judgment of curative effect

2.7.1. Primary outcomes. Total effective rate of cardiac function improvement (refer to the principle of clinical research on treating heart failure with new Chinese Medicine). Excellent: heart failure was essentially ameliorated or the NYHA classification increased by at least 2 levels; Valid: NYHA classification increased by 1 level; Invalid: NYHA classification remained the same before and after the treatment; Worsened: NYHA classification decreased by at least. Minnesota Living with Heart Failure Questionnaire . The higher the score, the worse the patient’s quality of life.

2.7.2. Secondary outcomes. Left ventricular ejection fraction , N-terminal pro-brain natriuretic peptide , tumor necrosis factor-alpha , interleukin-6 , 6-minute walk test.

2.7.3. Adverse reactions. Including liver and kidney function abnormalities and any uncomfortable symptoms (such as dizziness, nausea, etc) during treatment.

The above observation indicators were collected the day before and after treatment. All patients were followed up for 3 months, and data were collected according to the same standards in the first and third months.

2.8. Data collection and management

One or two assistants will collect and record the whole data. Personal information about potential participants and registered participants will be collected, shared, and kept in an independent storage room to protect confidentiality before, during, and after the test. The access to the database will be restricted to the researchers in this study team.

2.9. Statistical analysis

The collected data were statistically analyzed using SPSS 18.0 software. The enumeration data used the χ² test; the measurement data used the mean ± standard deviation (X ± S), the normal distribution used the independent sample t test, and the skewed distribution used the Mann-Whitney U test. When P <.05, the difference was considered statistically significant.

3. Discussion

Chronic heart failure is the main reason for hospitalization of elderly people worldwide, and has a negative impact on the quality of life of patients, with a high mortality rate. Although medicine and technology have made progress in the treatment of heart failure, the mortality, morbidity, and treatment costs of chronic heart failure are still high and rising year by year.
Therefore, it is urgent to explore safe and effective complementary and alternative therapies.

Traditional medicine believes that chronic heart failure is a chronic debilitating disease dominated by heart-yang deficiency, accompanied by blood stasis, drinking water, and turbid phlegm. The treatment should be to warm the yang to clear the collateral, promote qi and diuresis, and promote blood circulation.

Moxibustion is an external treatment method based on the acupuncture meridian theory, used to prevent and treat various chronic diseases. The thermal effect of the burning of moxa sticks stimulates the conduction of acupuncture through qi, which has the effect of warming yang and promoting the pulse, promoting qi, and activating blood.

This study verified the auxiliary efficacy of moxibustion by observing the comparison of the curative effect of moxibustion combined with conventional Western medicine and simple conventional Western medicine, and further explored the effect of moxibustion on the heart function and quality of life of patients with chronic heart failure.

Since this study is a single-center study, the regionalization of the included population may have a certain impact on the results. Therefore, more randomized controlled studies with more centers and large samples are needed to verify our conclusions.

Author contributions

Conceptualization: Jierong He and Miao Xu
Data curation: Jierong He and Lihong Jiao
Funding acquisition: Zhengyv Guo
Software: Lihong Jiao and Rui Gong
Supervision: Miao Xu and Rui Gong
Writing – original draft: Jierong He and Lihong Jiao
Writing – review & editing: Jierong He and Zhengyv Guo

References

[1] Agbor VN, Aminde LN, Tianyi FL, et al. Atrial fibrillation among adults with heart failure in sub-Saharan Africa – prevalence, incidence and all-cause mortality: a systematic review and meta-analysis protocol. BMJ Open 2019;9:e022320.
[2] Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev 2017;3:7–11.
[3] Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation 2019;139:e56–28.
[4] Wang J, Shi J, Wei J, et al. Safety and efficacy of Qishen granules in patients with chronic heart failure: study protocol for a randomized controlled trial. Trials 2017;18:468.
[5] Dokainish H, Teo K, Zhu J, et al. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. Lancet Glob Health 2017;5:e665–72.
[6] Shin KM, Park JE, Yook TH, et al. Moxibustion for prehypertension and stage I hypertension: a pilot randomized controlled trial. Integr Med Res 2019;8:1–7.
[7] Liu M, Zhang Q, Jiang S, et al. Warm-needling acupuncture and medicinal cake-separated moxibustion for hyperlipidemia: study protocol for a randomized controlled trial. Trials 2017;18:310.
[8] Chang XR, Peng L, Yi SX, et al. Association of high expression in rat gastric mucosal heat shock protein 70 induced by moxibustion pretreatment with protection against stress injury. World J Gastroenterol 2007;13:4335–9.
[9] Kawakita K, Shinbara H, Imai K, et al. How do acupuncture and moxibustion act? Focusing on the progress in Japanese acupuncture research. J Pharmacol Sci 2006;100:443–59.
[10] Yang M, Chen X, Bo L, et al. Moxibustion for pain relief in patients with primary dysmenorrhea: a randomized controlled trial. PLoS One 2017;12:e0170952.
[11] Li D, Li QL, Ma Q, et al. Effects of moxibustion on ventricular mass index and expression of apoptosis related proteins in myocardium of rats with chronic heart failure. Acupuncture Res 2018;43:80–5.
[12] Liu NN, Jia ZX, Wang J, et al. Moxibustion improves cardiac function by up-regulating autophagy-related proteins of cardiomyocytes in rats with chronic heart failure. Acupuncture Res 2019;44:25–30.
[13] Li Q, Wang W, Ma Q, et al. Moxibustion improves chronic heart failure by inhibiting autophagy and inflammation via upregulation of mTOR expression. Evid Based Complement Alternat Med 2021;2021:6635876.
[14] Liang B, Yan C, Zhang L, et al. The effect of acupuncture and moxibustion on heart function in heart failure patients: a systematic review and meta-analysis. Evid Based Complement Alternat Med 2019;2019:6074967.
[15] Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.
[16] Kusuma DY, Shatri H, Alwi I, et al. Validity and reliability studies of the Indonesian Version of the Minnesota Living with Heart Failure Questionnaire (MLHFQ): quality of life questionnaire for patients with chronic heart failure. Acta Med Indones 2019;51:26–33.
[17] Ponkowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–200.
[18] Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539–50.
[19] Chu HRYJ, Liu G. Elucidation of the national standard for Standardized Manipulation of Acupuncture and Moxibustion, Part 1 Moxibustion. Chin Acupunct Moxibustion 2010;30:499–504.
[20] Zheng X. The Principle of Clinical Research on Treating Heart Failure with New Chinese Medicine. Beijing: China Medical Science Press; 2002.
[21] Azad N, Lemay G. Management of chronic heart failure in the older population. J Geriatr Cardiol 2014;11:329–37.
[22] Mozaffarian D, Benjamin EJ, Go AS, et al. Executive Summary: Heart Disease and Stroke Statistics—2016 update: a report from the American Heart Association. Circulation 2016;133:447–54.
[23] Li Q-L, Ma Q, Li Y, et al. Effect of moxibustion on cardiac function and expression of autophagy-related proteins of cardio-myocytes in chronic heart failure rats. Acupuncture Res 2020;45:259–63.
[24] Zhang Y, He H, Wu B, et al. Observation on the effect of moxibustion on improving the condition and quality of life of patients with chronic heart failure. Chin J Mod Drug Appl 2019;13:201–2.